Compare GWAV & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWAV | ACXP |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.8M |
| IPO Year | 2014 | 2021 |
| Metric | GWAV | ACXP |
|---|---|---|
| Price | $3.80 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | 23.4K | ★ 47.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.35 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,098,036.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 116184.26 | N/A |
| 52 Week Low | $0.07 | $0.29 |
| 52 Week High | $24.00 | $8.34 |
| Indicator | GWAV | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 24.66 |
| Support Level | $3.29 | $0.30 |
| Resistance Level | $7.22 | $2.89 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 34.51 | 11.03 |
Greenwave Technology Solutions Inc through its subsidiary, is an operator of several metal recycling facilities in Virginia, Ohio and North Carolina. At these facilities, the company is involved in collecting, classifying, and processing raw scrap metal (ferrous and nonferrous) for recycling. The company involves collecting, classifying and processing appliances, construction material, end-of-life vehicles, boats, and industrial machinery and processing those items by crushing, shearing, shredding, separating, and sorting, into smaller pieces and categorize these recycled ferrous, nonferrous, and mixed metal pieces based on density and metal prior to sale.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.